Novel therapeutic agents for B-cell lymphoma: developing rational combinations
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel therapeutic agents for B-cell lymphoma: developing rational combinations
Authors
Keywords
-
Journal
BLOOD
Volume 117, Issue 5, Pages 1453-1462
Publisher
American Society of Hematology
Online
2010-10-27
DOI
10.1182/blood-2010-06-255067
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia
- (2010) I. M. Ghobrial et al. CLINICAL CANCER RESEARCH
- Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes
- (2010) O. A. O'Connor et al. CLINICAL CANCER RESEARCH
- Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia
- (2010) Irene M. Ghobrial et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic impact of protein kinase C β II expression in R-CHOP-treated diffuse large B-cell lymphoma patients
- (2010) Sari Riihijärvi et al. MODERN PATHOLOGY
- Aggressive Lymphomas
- (2010) Georg Lenz et al. NEW ENGLAND JOURNAL OF MEDICINE
- When 1 plus 1 equals 3 in VWD
- (2009) A. C. Goodeve BLOOD
- Bortezomib paradigm shift in myeloma
- (2009) D. J. McConkey BLOOD
- Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma
- (2009) N. Di Bella et al. BLOOD
- Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells
- (2009) T. Hideshima et al. BLOOD
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
- (2009) Thomas M. Habermann et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bendamustine: Rebirth of an Old Drug
- (2009) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- Gastrosplenic Fistula From Hodgkin's Lymphoma
- (2009) Carolyn D. Seib et al. JOURNAL OF CLINICAL ONCOLOGY
- High Numbers of Tumor-Infiltrating Programmed Cell Death 1–Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma
- (2009) Joaquim Carreras et al. JOURNAL OF CLINICAL ONCOLOGY
- Routine Omission of Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma ≤ 1 cm Is Not Justified
- (2009) Amod A. Sarnaik et al. JOURNAL OF CLINICAL ONCOLOGY
- Perifosine: Update on a novel Akt inhibitor
- (2009) Joell J. Gills et al. Current Oncology Reports
- Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
- (2008) A. Goy et al. ANNALS OF ONCOLOGY
- Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target
- (2008) R. M. Young et al. BLOOD
- Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma
- (2008) Stephen M. Ansell et al. CANCER
- Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation
- (2008) Dan Zhu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
- (2008) Jennifer S. Carew et al. CANCER LETTERS
- Bendamustine
- (2008) Greg L Plosker et al. DRUGS
- Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study
- (2008) Jonathan W. Friedberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
- (2008) Peter H. Wiernik et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma
- (2008) K. Sue Robinson et al. JOURNAL OF CLINICAL ONCOLOGY
- Thalidomide and lenalidomide: Mechanism-based potential drug combinations
- (2008) Sonia Vallet et al. LEUKEMIA & LYMPHOMA
- A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma
- (2007) F. Morschhauser et al. ANNALS OF ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search